Financials in USD. Standardized financial statements.
A compact view of how Cardiac Biotech Solutions Inc. turns revenue into operating income and net income.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $41,397 | $135,055 | $82,405 | $75,576 | $32,438 | $121,929 | $58,668 | $36,611 | $32,951 |
| Revenue Growth? | -69.3% | +63.9% | +9.0% | +133.0% | -73.4% | +107.8% | +60.2% | +11.1% | 0.0% |
| Cost of Revenue? | $0 | $0 | $42,239 | $149,241 | $9,809 | $720,033 | $43,823 | $414,656 | $227,349 |
| Gross Profit? | $41,397 | $135,055 | $40,166 | -$73,665 | $22,629 | -$598,104 | $14,845 | -$378,045 | -$194,398 |
| Gross Margin? | +100.0% | +100.0% | +48.7% | -97.5% | +69.8% | -490.5% | +25.3% | -1032.6% | -590.0% |
| Operating Expenses? | $1.37M | $1.73M | $2.14M | $1.80M | $2.97M | $401,346 | $77,414 | $103,347 | $175,363 |
| Operating Income? | -$1.33M | -$1.60M | -$2.10M | -$1.87M | -$2.94M | -$999,450 | -$62,570 | -$481,390 | -$369,760 |
| EBITDA? | -$1.69M | -$1.62M | -$2.10M | -$4.80M | -$3.98M | -$999,450 | -$59,545 | -$1.13M | -$369,285 |
| Income Before Tax | -$1.68M | -$1.63M | -$2.11M | -$6.34M | -$4.33M | -$999,452 | -$62,569 | -$1.13M | -$386,017 |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | -$4 | -$5 | $0 |
| Net Income? | -$1.68M | -$1.63M | -$2.11M | -$6.34M | -$4.33M | -$999,452 | -$62,569 | -$1.13M | -$386,017 |
| EPS? | $-0.01 | $-0.01 | $-0.02 | $-0.07 | $-0.06 | $-0.02 | $-0.00 | $-0.02 | $-0.01 |
| Diluted EPS? | $-0.01 | $-0.01 | $-0.02 | $-0.07 | $-0.06 | $-0.02 | $-0.00 | $-0.02 | $-0.01 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality